Alphatec COO Lish Scott sells $315,434 in stock

Lish Scott, the Chief Operating Officer of Alphatec Holdings , Inc. (NASDAQ:ATEC), recently sold a portion of the company’s common stock. According to a filing with the Securities and Exchange Commission, Scott sold 27,453 shares at a weighted average price of $11.49 per share, totaling approximately $315,434. The medical technology company, currently valued at $1.6 billion, has seen its stock surge nearly 80% over the past six months, according to InvestingPro data.

The sale was executed as part of a pre-established Rule 10b5-1 trading plan, which Scott adopted in December 2022 and amended in August 2023. This plan was designed to help manage tax withholding obligations arising from the vesting of restricted stock units. After this transaction, Scott retains ownership of 867,677 shares in the company. The company maintains a healthy financial position with a current ratio of 2.32, indicating strong liquidity to meet short-term obligations.

This move is part of routine financial management and does not necessarily reflect Scott’s outlook on the company’s future performance. With revenue growing at 27% year-over-year and an overall financial health score rated as GOOD by InvestingPro, which offers 6 additional key insights about ATEC’s valuation and growth prospects in its comprehensive Pro Research Report.

In other recent news, Alphatec Holdings announced strong preliminary financial results for the fourth quarter and full year of 2024. The company reported an approximate 27% increase in total revenue for 2024, driven by a 29% growth in surgical revenue and a 19% rise in surgical volume. Alphatec’s cash balance as of December 31, 2024, was approximately $139 million, marking a significant increase from the previous quarter.

Looking ahead, Alphatec anticipates its full-year 2025 revenue to reach $732 million, which would represent a 20% growth compared to 2024. This projection includes surgical revenue of approximately $657 million and EOS revenue around $75 million. The company also expects to achieve positive free cash flow with an adjusted EBITDA of $75 million for the year.

Needham analyst David Saxon responded positively to the preannouncement, raising the price target on Alphatec to $16.00 from $13.00 while maintaining a Buy rating. Piper Sandler analysts also expressed optimism for Alphatec, anticipating positive fiscal year outlooks. Furthermore, Dave Demski, who holds board membership at Alphatec, was recently appointed as an independent director at Paragon 28, Inc., further strengthening the strategic oversight at Alphatec.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.